Back to search results

Iodine-124 PET/CT Scan for Metastatic Thyroid Cancer

This study is testing a new way to look at metastatic thyroid cancer using a special imaging test called a PET/CT scan with Iodine-124. This test helps doctors see how much radioactive iodine the cancer cells are taking up. If the test shows your cancer takes up enough radioactive iodine, your treatment will continue as usual. If it shows low uptake, your doctors might decide that a different treatment would be better for you. This study is looking for adults who have thyroid cancer that has spread (metastatic) or is suspected to have spread, and who have already had their thyroid removed. The main goal is to see how individual cancer spots respond to this imaging test over one year. The study plans to enroll 60 participants, and its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment or intervention. It plans to enroll 60 participants.
What's involved
You would receive two injections of rhTSH, followed by a single oral dose of Iodine-124. You would then have up to four whole-body PET scans over a few days.
Compensation
Not stated in the trial record.
Follow-up
The study measures the response of individual lesions at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03647358

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Recruiting
PHASE1Ages 18+InterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~60 participants
Updated 2026-04-14 on ClinicalTrials.gov
What's tested:PET/CT ScanIodine-124

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
number of individual lesions response
Measured over 1 year

Conditions

Thyroid Carcinoma
Metastatic Thyroid Carcinoma

Explore related trials

Thyroid Gland Carcinoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Ravinder Grewal, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Ravinder Grewal, MD
[email protected]
212-639-2872
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults with thyroid carcinoma confirmed by pathology.
Adult thyroid carcinoma patients who have undergone total thyroidectomy
Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131I uptake, and are about to undergo Thyrogen-assisted dosimetry, unless Thyrogen-assisted dosimetry is not required per standard of care.
The patient and physician are planning to administer 131I for therapy if persistent radioiodine-avid metastases are present.
All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, FDG PET/CT, or CT scanning.

Exclusion

Age less than 18 years.
Patients who are pregnant.

What this trial measures

  • number of individual lesions response1 year

    This will be accomplished using a logistic regression model using lesion as the unit of analysis and adjusting for possible correlation between lesions on the same patient using a random effect at the patient level. by RECIST 1.1